Summary: “It’s the first time we’ve seen a radically new treatment of this scale in mental health in the last 40 years,” explains Brad Burge during an interview on a recently aired 60 Minutes Australia exclusive about the therapeutic potential of MDMA-assisted psychotherapy for PTSD. The episode follows the experience of a former participant in a Phase 3 clinical trial as well as interviews Brad Burge of MAPS and Erik Sienknecht, Psy.D., a MAPS-sponsored therapist working on Phase 3 trials of MDMA-assisted psychotherapy for PTSD. “It is going to change the face of psychiatry,” says Sienknecht.
Originally appearing here.